Compare LQDA & AKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LQDA | AKR |
|---|---|---|
| Founded | 2004 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.7B |
| IPO Year | 2018 | 1993 |
| Metric | LQDA | AKR |
|---|---|---|
| Price | $37.68 | $21.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 3 |
| Target Price | ★ $38.60 | $22.00 |
| AVG Volume (30 Days) | ★ 1.9M | 1.6M |
| Earning Date | 11-03-2025 | 02-10-2026 |
| Dividend Yield | N/A | ★ 3.80% |
| EPS Growth | N/A | ★ 18.54 |
| EPS | N/A | ★ 0.12 |
| Revenue | $69,216,000.00 | ★ $389,489,000.00 |
| Revenue This Year | $1,005.03 | N/A |
| Revenue Next Year | $204.13 | $16.18 |
| P/E Ratio | ★ N/A | $170.50 |
| Revenue Growth | ★ 343.41 | 6.01 |
| 52 Week Low | $11.26 | $16.98 |
| 52 Week High | $41.57 | $24.95 |
| Indicator | LQDA | AKR |
|---|---|---|
| Relative Strength Index (RSI) | 60.22 | 59.97 |
| Support Level | $29.41 | $20.67 |
| Resistance Level | $41.57 | $21.20 |
| Average True Range (ATR) | 3.03 | 0.45 |
| MACD | 0.43 | 0.00 |
| Stochastic Oscillator | 68.38 | 84.80 |
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
Acadia Realty Trust is a real estate investment trust that specializes in the operation, management, leasing, renovation, and acquisition of shopping centers and mixed-use properties with retail components. The company operates through three segments: Core Portfolio segment consists primarily of high-quality retail properties located primarily in high-barrier-to-entry, densely-populated metropolitan areas with a long-term investment horizon; Investment Management segment holds primarily retail real estate in which the company co-invests with high-quality institutional investors; and Structured Financing segment consists of earnings and expenses related to notes and mortgages receivable Fees earned by the company as the general partner or managing member through Investment Management.